Literature DB >> 2673607

Clinical pharmacokinetics of iron preparations.

E Harju1.   

Abstract

The principle of iron conservation is the basis of iron metabolism; the normal basal loss of iron from the body is about 1 mg daily in a 70 kg man and 0.8 mg in a 55 kg woman. Iron is lost mainly by the menstrual and gastrointestinal routes. The total iron requirement during pregnancy is 800 mg; in the last month the requirement may amount to 7 to 8 mg/day. Supplementary iron is recommended for many menstruating women, and during the latter part of pregnancy. Correct fetal iron metabolism is ensured by proper maternal iron status, although there are contradictory opinions and findings about the relationship between maternal and fetal iron metabolism. Preterm infants fed on breast milk have a negative iron balance, and require an iron intake of about 0.6 mg/kg/day, and 3.4 mg/1 g haemoglobin, to compensate for intestinal and venesection iron losses, respectively. The absorption of supplementary iron by the preterm infant is a linear function of intake. Preterm infants do not require iron supplements when given repeated blood transfusions. During lactation the total iron losses of the mother are 1 mg/day, and thus no supplementary iron is needed if the iron metabolism has been in balance during the pregnancy. Serum ferritin concentration decreases continuously when iron stores in the body are reduced, and totally empty iron stores are the only known reasons for low serum ferritin concentration. Despite depleted iron stores, serum ferritin concentration can be normal or higher than normal in protein-energy malnutrition, up to 3 months after major surgery, in acute liver damage, in some patients with prolonged hyperglycaemia due to diabetes mellitus, in acute lobar pneumonia, active pulmonary tuberculosis and rheumatoid arthritis on gold therapy, in sepsis secondary to marrow hypoplasia induced by chemotherapy, in heavy drinkers and for a few days after myocardial infarction. In haemochromatosis, iron is deposited in liver (producing fibrosis), pancreas, endocrine glands and heart. The rise in the level of iron in the body is due to increased absorption and/or increased intake. This pathology may occur in transfusions, in alcoholism (especially when alcoholic beverages are contaminated with iron and the diet is low-protein), in several liver diseases, in congenital transferrin deficiency and in idiopathic disease. Patients susceptible to haemochromatosis should receive a low-iron diet. Serum ferritin determination may be helpful in early identification of susceptible members of a family with idiopathic familial haemochromatosis, but transferrin saturation is not a good indicator of either iron depletion or iron overload.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2673607     DOI: 10.2165/00003088-198917020-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  89 in total

1.  Binding of zinc and iron to wheat bread, wheat bran, and their components.

Authors:  F Ismail-Beigi; B Faraji; J G Reinhold
Journal:  Am J Clin Nutr       Date:  1977-10       Impact factor: 7.045

2.  A comparison between concentrations of free erythrocyte protoporphyrin and serum ferritin during development of iron deficiency by phlebotomy in polycythaemia vera patients.

Authors:  G Birgegård; C H de Verdier; C Högman
Journal:  Scand J Clin Lab Invest       Date:  1987-10       Impact factor: 1.713

3.  Genetic linkage and hemosiderosis.

Authors:  K K Kidd
Journal:  N Engl J Med       Date:  1979-07-26       Impact factor: 91.245

4.  Ferritin in erythrocytes and plasma of patients with iron overload.

Authors:  H H Bodemann; R F Tanzi-Fetta; H Schröter-Urban; B A Volk; J Keul; G W Löhr
Journal:  Blut       Date:  1985-07

5.  Lack of iron stores in patients with diseases of the gastrointestinal tract.

Authors:  E Harju; H Lindberg
Journal:  Surg Gynecol Obstet       Date:  1985-10

6.  Comparison between serum ferritin and computed tomographic densities of liver, spleen, kidney and pancreas in beta-thalassaemia major.

Authors:  M A Babiker; P J Patel; Z A Karrar; M H Hafeez
Journal:  Scand J Clin Lab Invest       Date:  1987-11       Impact factor: 1.713

7.  Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations.

Authors:  J P Kaltwasser; E Werner; M Niechzial
Journal:  Arzneimittelforschung       Date:  1987-01

8.  Iron absorption and haemoglobin regeneration studies on a new sustained release iron preparation.

Authors:  A Norrby; L Sölvell
Journal:  Scand J Haematol       Date:  1971

9.  An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload.

Authors:  G M Addison; M R Beamish; C N Hales; M Hodgkins; A Jacobs; P Llewellin
Journal:  J Clin Pathol       Date:  1972-04       Impact factor: 3.411

10.  Serum ferritin in haemodialysis patients: is there a relationship to 'haemochromatosis alleles' HLA A3, B7, B14?

Authors:  E R Maher; J R Curtis
Journal:  Nephron       Date:  1986       Impact factor: 2.847

View more
  9 in total

Review 1.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

2.  Association of genetic variants with response to iron supplements in pregnancy.

Authors:  Rekha Athiyarath; Kalaiselvi Shaktivel; Vinod Abraham; Daisy Singh; Joseph Dian Bondu; Aaron Chapla; Biju George; Alok Srivastava; Eunice Sindhuvi Edison
Journal:  Genes Nutr       Date:  2015-05-30       Impact factor: 5.523

3.  Methyldopa kinetics before and after ingestion of methyldopa for eight weeks.

Authors:  N R Campbell; A Skerjanec; Y Tam; S Robertson; E Burgess
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Ferrous sulphate interacts with captopril.

Authors:  J P Schaefer; Y Tam; B B Hasinoff; S Tawfik; Y Peng; L Reimche; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

5.  Clinical pharmacokinetics of ferric natural protein in iron-deficient females.

Authors:  A López de Ocáriz; M Simón; P Balsera; M Diaz; E García Quetglas; M Gimeno; P Coronel; J Honorato
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.

Authors:  Oliver Pohl; R Howard Zobrist; Jean-Pierre Gotteland
Journal:  Reprod Sci       Date:  2014-09-16       Impact factor: 3.060

7.  Perioperative optimization of patients undergoing bariatric surgery.

Authors:  C E Owers; Y Abbas; R Ackroyd; N Barron; M Khan
Journal:  J Obes       Date:  2012-07-05

8.  Comparison study of oral iron preparations using a human intestinal model.

Authors:  Mohammed Gulrez Zariwala; Satyanarayana Somavarapu; Sebastien Farnaud; Derek Renshaw
Journal:  Sci Pharm       Date:  2013-06-21

9.  Rapid diagnostic algorithms as a screening tool for tuberculosis: an assessor blinded cross-sectional study.

Authors:  Franz Ratzinger; Harald Bruckschwaiger; Martin Wischenbart; Bernhard Parschalk; Delmiro Fernandez-Reyes; Heimo Lagler; Alexandra Indra; Wolfgang Graninger; Stefan Winkler; Sanjeev Krishna; Michael Ramharter
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.